Julie Goonewardene

Chairwoman


Ms. Goonewardene is currently Vice Chancellor for Innovation & Strategic Investment at the University of Texas System (UTS), AMA Board, MBI Board and US Commerce Advisor. In addition, Julie has a track record as an experienced entrepreneur, having co-founded and served as President and CEO of Cantilever Technologies, a venture-backed software company that was successfully acquired. Cantilever’s customers were Fortune 500 companies. Prior to Cantilever, she was President of the Strategic Systems Group (SSG), a boutique information technology consulting firm, and co-founder of Technology Solutions (TSC), a professional IT services firm which went public three years after its inception. In addition to her role at UTS, Ms. Goonewardene is an author, frequent speaker and consultant on entrepreneurship and innovation. Based on success in these areas, Julie was elected to the Board of Trustees for the American Medical Association (AMA), the Board of Directors of the Personalized Medicine Coalition and Matrix-Bio and is an advisor on the National Advisory Council on Innovation and Entrepreneurship (NACIE) Board to the US Commerce Secretary. As a first generation American born to Sri Lankan and Australian parents, she brings a unique global perspective to her endeavours.




Peter Keeling

Chief Executive Officer


As Chief Executive Officer of Diaceutics, Peter has driven the organization from its inception in 2005 to become a leader in innovative solutions that enable pharma to leverage diagnostic testing globally. He has overseen the expansion and development of Diaceutics to support pharma therapy and diagnostic commercialization via a worldwide team.

Peter recognised early on that precision medicine would be an increasingly large part of the drug development paradigm, representing a shift in how the pharmaceutical industry operates. Today, he is a thought leader in precision medicine commercialization and Diaceutics provides the top 20 precision medicine pharma companies with the data, analytics and global lab implementation services required to align biomarker and diagnostic demand with therapy, patient and revenue targets in key markets.

Peter’s role with Diaceutics complements over thirty years’ experience in international healthcare which began at GSK and Diagnology. He has operated and led companies and teams in the US, Europe, Asia and BRIC countries, inspiring product innovation and global launches while repeatedly delivering high corporate value growth for shareholders.

Peter has spent two extended periods in applied industrial research, including a year at MIT’s Pharmaceutical Program at the Sloan School of Management in Boston. He has also published widely and is a respected speaker at precision medicine events around the world.




Ryan Keeling

Chief Operating Officer


As Chief Operating Officer of Diaceutics, Ryan is responsible for overseeing operations across the company.

Ryan joined Diaceutics in 2009 and has utilised his expertise in commercial, data and pharma strategy to work on multiple diagnostic/therapy launches since then. Ryan is focused on providing strategic advice to our pharma clients that is supported with a strong background in market access and reimbursement.




Philip White

Chief Financial Officer


As Chief Financial Officer of Diaceutics, Philip has responsibility for all administrative, financial and risk management operations. He works closely with the management team and Board of Directors to develop and implement strategies across the organization. In addition, Philip is responsible for maintaining compliance with US, UK and Republic of Ireland financial reporting, taxation and corporate governance standards.

Philip has over ten years’ financial and management experience as the Finance Director of a company in a global export market, as well as significant experience in product development, planning and product launch. He is an acting board member of a UK charity and has significant experience at board level in the charitable and not-for-profit sector. He is a member of the Institute of Chartered Accountants in Ireland, an associate member of the Institute of Taxation and a member of the Institute of Directors.